We are happy to announce that a core patent from ETH Zurich which is exclusively licensed to Biognosys was granted in the US (US8501421 B2) and the corresponding application is pending in Europe. The patent describes a method (Picotti et al. 2009) for efficient development of SRM/MRM assays using, for example, synthetic peptide libraries.
With increasing demand for quantitative multiplexed proteomics the development and validation of assays becomes a bottleneck. This patent enables Biognosys to protect a key process in high-content targeted proteomics experiments.